Jacqueline Sharon

Jacqueline Sharon

Auto-generated profile, based on publicly available information

Jacqueline Sharon

Boston University School of Medicine

Research Focus & Metrics

Academic Career Length

51Years (1976-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 April 2006 in Biotechnology and Bioengineering
Verified
Journal Article
Closed access
PDF file
FWFinn C. Wiberg
Finn C. Wiberg
SRSøren K. Rasmussen
Søren K. Rasmussen
TFTorben P. Frandsen
Torben P. Frandsen
LRLone K. Rasmussen
Lone K. Rasmussen
KTKaja Tengbjerg
Kaja Tengbjerg
ATAnne B. Tolstrup
Anne B. Tolstrup

1 June 1990 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
JSJ Sharon
J Sharon
The basis for the 200-fold difference in affinity between two hybridoma antibodies specific for the hapten p-azophenylarsonate (Ars) that have diversified by somatic hypermutation was examined. Oligonucleotide-directed mutagenesis was used to sequentially convert the nucleotide sequence of the lower-affinity antibody into that of the higher-affinity one, and the mutant antibodies generated by transfection of hybridoma cells were analyzed for affinity to Ars-tyrosine. The data showed that out of the 19 amino acid differences between the two hybridoma antibodies, the affinity increase could be reproduced by three heavy-chain substitutions that are present in the high-affinity antibody. The combined effect on affinity of amino acid substitutions was generally found to reflect their individual effects. Although the light chain of the high-affinity antibody did not seem to play a major role in the affinity increase, its contribution varied with the kind and number of heavy-chain substitutions. The results hold promise for antibody engineering and are consistent with a stepwise acquisition of somatic hypermutations in which the existing structural context of an antibody most likely influences the affinity-based selection of later substitutions. They further suggest that many substitutions may be tolerated in vivo during the antigen-driven selection process, even though they confer on the antibody no affinity increase.

16 April 1991 in Biochemistry
Verified
Journal Article
Closed access
RSRoland K. Strong
Roland K. Strong
RCRobert Campbell
Robert Campbell
DRDavid R. Rose
David R. Rose
GPGregory A. Petsko
Gregory A. Petsko
JSJacqueline Sharon
Jacqueline Sharon
MMMichael N. Margolies
Michael N. Margolies

1 December 1982 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
CBC L Berger
C L Berger
SMS Morrison
S Morrison
ACA Chu
A Chu
JPJ Patterson
J Patterson
AEA Estabrook
A Estabrook
RER L Edelson
R L Edelson
Two murine monoclonal antibodies (BE1 and BE2), produced by using leukemic helper T cells from a patient with cutaneous T-cell lymphoma (CTCL) as immunogens, reacted selectively with CTCL lymphocytes and some transformed cultured lymphocytes, as determined by radioimmunoassay (RIA) and indirect immunofluorescence (IIF). BE1 reacted significantly (P less than or equal to 0.001) with leukemic CTCL lymphocytes and with CTCL cells from infiltrated lymph nodes (RIA, mean +/- SD = 776 +/- 275 cpm), as compared with background counts (263 +/- 68). BE1 binding to normal blood mononuclear cells (RIA, mean +/- SD = 283 +/- 58 cpm) was indistinguishable from background. BE1 also reacted with Epstein-Barr virus (EBV)-transformed B-cell lines (RIA, mean +/- SD = 794 +/- 230) and some long-term T-cell lines. BE1 did not react with the majority of lymphoid cell lines or tumor cell lines tested. BE1 also did not react with any normal tissues screened by IIF. BE1 precipitated a molecule from CTCL cells that, under reducing conditions, has two components with molecular mass of 27,200 and 25,800 D. BE2 also reacted significantly (P less than or equal to 0.001) with CTCL cells from two of four patients (RIA, mean +/- SD = 519 +/- 113 cpm). The binding of BE2 to normal mononuclear cells was indistinguishable from background (309 +/- 38 cpm). BE2 also reacted with an antigen present on EBV-B-cell lines (RIA, mean +/- SD = 654 +/- 194) and MOLT 3 and HUT 78 T-cell lines. BE2 reacted with an antigen expressed on a subpopulation of lymphocytes from five of eight patients with B-cell CLL studied by IIF (mean +/- SD = 18 +/- 6). Other long-term T-cell lines and tumor cell lines studied by IIF were unreactive with BE2. BE2 did not react with any of the normal tissues studied. BE2 precipitated a molecule (78,000 D) from CTCL cells and EBV-B cells with a single component under reducing conditions. Immunoperoxidase-labeled BE1 and BE2 reacted with CTCL cells in frozen sections of infiltrated lymph nodes and skin. In addition, BE1 and BE2 reacted with blood lymphocytes from 16 of 21 patients whose CTCL had otherwise been considered localized to skin. These two monoclonal antibodies react with tumor antigens associated with CTCL and appear to be useful in the diagnosis of this disorder.

15 January 1989 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
JSJ Sharon
J Sharon
MGM L Gefter
M L Gefter
LWL J Wysocki
L J Wysocki
MMM N Margolies
M N Margolies
Two mouse mAb specific for the hapten p-azophenylarsonate and encoded by the same combination of germ-line V, D, and J genes differ 200-fold in affinity for hapten. We determined the amino acid sequences of the V regions of the high affinity antibody and compared them to the published sequences of the low affinity antibody which is not somatically mutated. Of 19 amino acid substitutions, two, Ile57 and Thr58 in the H chain, also occur, either alone or together, in other somatically mutated antibodies specific for p-azophenylarsonate; these antibodies have been independently isolated. Introduction of either one of these mutations alone into the low affinity antibody by oligonucleotide-directed mutagenesis increased the antibody affinity for hapten three- to fourfold, whereas introduction of both mutations together conferred an eightfold increase in affinity. These results support the hypothesis that somatic mutations are selected on the basis of the affinity for antigen that they confer, and suggest that even relatively small increases in affinity may be selected, probably in a sequential manner.

10 April 2014 in Immunology
Verified
Journal Article
Closed access
PDF file
JSJacqueline Sharon
Jacqueline Sharon
MRMichael J. Rynkiewicz
Michael J. Rynkiewicz
ZLZhaohua Lu
Zhaohua Lu
CYChiou-Ying Yang
Chiou-Ying Yang